Released on = February 14, 2007, 6:40 am

Press Release Author = MACOPHARMA

Industry = Pharmaceuticals

Press Release Summary = MacoPharma SA (MacoPharma) announced that the
Paul-Ehrlich-Institut (PEI) in Germany has given the first approval for plasma
treated with the THERAFLEX Methylene Blue procedure (THERAFLEX MB-Plasma) to the
University Clinics, Institute for Transfusion Medicine, Essen / Germany.

This approval is the first one in Germany, and follows approvals already obtained in
other countries. The THERAFLEX MB-Plasma technology received CE marking in Europe in
2001.

"MacoPharma is committed to providing products that safeguard the blood components
supply" says André Pollet, COC of MacoPharma, "this approval will allow MacoPharma
to help to prepare a safer plasma and reduce the risk of pathogens transmission
through transfusion". "This first approval in Germany is a major milestone for the
development of the technology in other German places and in the world".


Press Release Body = About THERAFLEX MB-Plasma:

Despite thorough donor screening and extensive testing procedures, the transmission
of pathogens through transfusion remains a real and constant risk. This risk can be
substantially reduced by the use of pathogen reduction technology.
Within the THERAFLEX range, MacoPharma has developed the MB-Plasma integrated system
which allows the reduction of pathogens such as HIV and Hepatitis (B & C) viruses in
single units of plasma, combining the advantages of both viral reduction and single
unit treatment.

About MacoPharma:

MacoPharma is an innovator in global healthcare with expertise in the fields of
transfusion and infusion. The Company has become the largest supplier of in-line
leucodepletion filtration sets in Europe and is expanding its efforts into the
biotechnology field by developing products for cell expansion, in addition to
cell/organ processing and freezing. Headquartered in the Lille metropolitan area
(France), MacoPharma has three manufacturing facilities in Europe and its products
are now sold in more than 55 countries worldwide. One of MacoPharma\'s aims is to
provide a comprehensive range for the reduction of infectious agents in plasma,
platelets and red cells. This is consistent with the MacoPharma product development
strategy of the continuous quest, through partnerships, for improved safety,
efficacy, and quality of transfusion, infusion and biotherapy.
www.macopharma.com

THERAFLEX MB-Plasma® is a registered trade mark of MacoPharma in Europe for a
patented proprietary procedure and equipment to reduce pathogens in Plasma.

THERAFLEX MB-PlasmaT is a worldwide brand name of MacoPharma.

Contact details:

Dr. S. Reichenberg / Dr. W. Walker
MacoPharma International GmbH
Robert-Bosch-Straße 11
63225 Langen / Germany
Phone: +49-6103-9008-64 (Dr. Reichenberg); stefan.reichenberg@macopharma.de.
Phone: +49-6103-9008-24 (Dr. Walker); wolfram.walker@macopharma.de

Guillaume de Saint Martin
MacoPharma SA
Rue Lorthiois
59420 Mouvaux / France
Phone: +33-3-2011-8430; guillaume.desaintmartin@macopharma.com


Web Site = http://www.macopharma.com

Contact Details = MacoPharma SA
Rue Lorthiois
59420 Mouvaux / France
Phone: +33-3-2011-8430